ALERT: Your health is top priority. We’re committed to providing reliable COVID-19 resources to keep you informed and safe.

C-QUR Mesh

C-QUR mesh has a unique fish-oil-derived coating. Atrium Medical manufactures C-QUR mesh. Studies link C-QUR mesh products to high infection rates. Atrium recalled 145,000 C-QUR units in 2013, citing packaging problems. The mesh has also been the subject of FDA warnings and a federal injunction.

Atrium Medical manufactures several different C-QUR hernia mesh products. The company claims its unique, absorbable coating prevents many hernia mesh complications. But some studies suggest C-QUR has a higher infection rate than other meshes. Patients have also reported complications to the U.S. Food and Drug Administration.

FDA inspectors found manufacturing violations during several inspections of Atrium’s plant. The agency sent the company a warning letter after a 2012 inspection. The agency sought an injunction to stop C-QUR manufacturing in 2013.

Maquet Getinge Group purchased the company in 2011 for $680 million. Atrium continues manufacturing C-QUR at its plant in New Hampshire.

What Is C-QUR Surgical Mesh?

Atrium Medical manufacturers C-QUR mesh products for hernia and other soft tissue repair. These include chest wall reconstruction, and traumatic and surgical wounds. C-QUR meshes are permanent implants.

Examples of Atrium C-QUR mesh
Examples of Atrium C-QUR hernia mesh

Atrium intended C-QUR for inguinal hernia repair using the IPOM surgical technique. This technique places mesh between the hernia wound and the intestine. It can create an adhesion risk. Adhesions are scar-like tissue that connect tissue that wouldn’t normally be connected.

C-QUR mesh has a fish-oil-derived coating. Atrium claims the fish oil prevents inflammation and adhesions. But studies show it has higher adhesion and infection rates than many other brands.

What Is C-qur Made Of?
C-QUR mesh is made of polyethylene plastic and coated with Omega-3 fatty acid fish oil.

FDA 510(k) Clearance

The FDA cleared C-QUR mesh through its 510(k) process in 2006. The process lets manufacturers skip more rigorous testing requirements.

It allows a new device on the market if its maker shows that it is “substantially similar” to one already approved. Since 2006, Atrium produced several other C-QUR variations.

C-QUR Surgical Mesh Products Include:
  • C-QUR Mesh
  • C-QUR Mosaic
  • Vitamesh
  • C-QUR Tacshield
  • C-QUR V-Patch
  • C-QUR CentriFX
  • C-QUR FX Mesh

Adhesions and Other Complications

Atrium claimed that the fish-oil-based coating would reduce adhesions and reactions. But people still reported these and other complications to the FDA. Some studies have shown higher infection rates linked to C-QUR compared to other mesh.

Reports of C-QUR Complications Include:
  • Adhesion to the bowels
  • Bowel obstructions
  • Fistula formation (an abnormal connection, such as between the abdominal wall and intestines)
  • Hematoma (blood collecting in tissue)
  • Infections
  • Inflammation or swelling
  • Seroma (buildup of fluid under the skin)
  • Severe allergic reactions
  • Severe pain

C-QUR Safety And Efficacy Studies

C-QUR’s fish-oil-based coating is a bioabsorbable film. Atrium claimed it would keep mesh from touching internal organs. This would prevent mesh adhesions. Atrium claimed the coating “has been shown to minimize tissue attachment to mesh.”

In one of its 2011 product brochures, Atrium said the coated mesh provides patients with “a durable, long lasting repair, and a more natural healing experience.”

Atrium’s studies found its coated mesh had a “minimal inflammatory response” compared to non-coated meshes. It also performed as well as or better than several commercially available hernia mesh products such as Ethicon’s Proceed and C.R. Bard’s Composix for tissue attachment and mesh contraction. Mesh contraction can cause pain and other issues. C-QUR mesh had lower rates of mesh contraction, according to the product brochure.

But some studies question the safety and effectiveness of Atrium C-QUR hernia mesh.

One team of researchers tested C-QUR on animals. Researchers found that the infection rate was higher with C-QUR mesh than with other mesh.

One animal died less than two weeks after implantation. Researchers said the mesh caused bowel obstruction and was to blame. Studies also show that the coating interferes with tissue growing into the mesh.

“After 30 days there was a significant increase in adhesions and immune response around the mesh implants.”

Dr. M.H. Schreinemacher and colleagues in a 2009 issue of the British Journal of Surgery

A 2016 case study looked at a 61-year-old woman who received C-QUR mesh for an incisional hernia repair. After 10 months, she complained of pain and upper abdomen discomfort.

The authors performed a revision surgery. They found thick, oozing adhesions around the mesh.

The doctors removed the mesh and part of her stomach. They determined that the mesh and fish-oil coating created an inflammatory response. They also blamed it for the adhesions.

Lawsuit Information
Multiple lawsuits claim complications stemming directly from Atrium C-QUR hernia mesh, including allergic or inflammatory responses in patients. Learn more.
View Lawsuits

Manufacturer Recalls

In 2013, Atrium announced a series of recalls for packaging problems. The recalls affected more than 145,000 C-QUR units. The recalled products included C-QUR V Patch, TacShield, Edge and standard C-QUR Meshes.

Atrium cited “excessive humidity for an extended period of time” in its recall notice. The problem could cause the mesh coating to stick to its “inner handling sleeve.”

FDA’s Atrium C-QUR Inspections

The FDA received C-QUR complications reports as early as 2008. The agency inspected the C-QUR manufacturing plant four times between 2009 and 2013.

Each time, inspectors reported violations of federal regulations. Problems included monitoring, reporting and manufacturing issues.

The FDA sent Atrium a warning letter in 2012. Warning letters are among the most serious actions the FDA takes against manufacturers.

The letter cited manufacturing and sterilization issues. Inspectors reported human hair and other foreign matter in supposedly sterilized C-QUR. The letter accused Atrium of changing its manufacturing process without testing the changes.

FDA inspectors found violations at Atrium’s C-QUR plant during different inspections in 2009, 2010, 2012 and 2013.

DOJ, FDA Block C-QUR Manufacturing

A 2013 inspection turned up similar violations to what the FDA found in earlier ones. Atrium had promised to fix those problems following each inspection.

Because it did not, the FDA decided to take stronger action. The agency and the Department of Justice sought an injunction against Atrium. A court agreed and blocked C-QUR manufacturing until Atrium fixed the problems.

Atrium agreed to a consent decree. The company agreed to pay $6 million dollars for the problems listed in the injunction. Atrium agreed to pay another $6 million unless it corrected problems at the plant.

Atrium C-QUR Hernia Mesh Lawsuits

People who suffered C-QUR complications filed hernia mesh lawsuits in several courts. In 2016, hernia mesh lawyers sought a multidistrict litigation (MDL) for C-QUR cases.

MDLs combine several similar lawsuits. They can move through the legal process more quickly and efficiently.

C-QUR Lawsuit Claims
C-QUR lawsuits claim the mesh incited an allergic or inflammatory response.

The MDL panel selected the District of New Hampshire as the court for C-QUR litigation. People had filed several of the lawsuits in the district already. Atrium is also headquartered there.

As of July 2020, there were 2,241 lawsuits in the MDL. The first C-QUR lawsuit was scheduled for trial in 2020, but Atrium asked the court to move the trial to January 2021 because of the COVID-19 pandemic.

Examples of Atrium C-QUR mesh
C-Qur Facts
  1. Uses Surgical hernia repair
  2. Complications Adhesion, bowel obstructions, fistulas, hematoma, infections, swelling, seroma, severe allergic reactions, severe pain
  3. Manufacturer Atrium Medical

Please seek the advice of a medical professional before making health care decisions.

Terry Turner
Written By Terry Turner Writer

Terry Turner has been writing articles and producing news broadcasts for more than 25 years. He covers FDA policy, proton pump inhibitors, and medical devices such as hernia mesh, IVC filters, and hip and knee implants. An Emmy-winning journalist, he has reported on health and medical policy issues before Congress, the FDA and other federal agencies. Some of his qualifications include:

  • American Medical Writers Association (AMWA) and The Alliance of Professional Health Advocates member
  • Centers for Disease Control and Prevention Health Literacy certificates
  • Original works published or cited in Washington Examiner, MedPage Today and The New York Times
  • Appeared as an expert panelist on hernia mesh lawsuits on the BBC
Edited By
Emily Miller
Emily Miller Managing Editor
Medically Reviewed By
Dr. John A. Daller
Dr. John A. Daller American Board of Surgery

34 Cited Research Articles writers follow rigorous sourcing guidelines and cite only trustworthy sources of information, including peer-reviewed journals, court records, academic organizations, highly regarded nonprofit organizations, government reports and interviews with qualified experts. Review our editorial policy to learn more about our process for producing accurate, current and balanced content.

  1. Maquet Cardiovascular. (2011, November 7). Maquet Cardiovascular Completes Acquisition of Atrium Medical Corporation. Press Release. Retrieved from
  2. Atrium Medical Corporation. (2011, October 3). Atrium Medical Agrees to Be Acquired for $680 Million by Getinge Group [Press Release]. Retrieved from
  3. U.S. Food and Drug Administration. (2013, August 9). Class 2 Device Recall CQUR Edge Mesh. Retrieved from
  4. U.S. Food and Drug Administration. (2013, July 19). Class 2 Device Recall; CQUR VPatch Mesh. Retrieved from
  5. U.S. Food and Drug Administration. (2018, February 4). Hernia Surgical Mesh Implants. Retrieved from
  6. Sherwinter, D.A. et al. (2016). Laparoscopic Inguinal Hernia Repair. Retrieved from
  7. Society of American Gastrointestinal and Endoscopic Surgeons. (n.d.). Laparoscopic Inguinal Hernia Repair. Retrieved from
  8. Brown, C.N. & Finch, J.G. (2010). Which mesh for hernia repair? Retrieved from
  9. Atrium. (n.d.). C-QUR Mesh. Retrieved from
  10. Atrium. (n.d.). C-QUR Brochure. Retrieved from
  11. MedlinePlus. (2017, May 31). Hernia. U.S. National Library of Medicine. NIH. Retrieved from
  12. U.S. Food and Drug Administration. (2017, December 28). Hernia Surgical Mesh Implants. Retrieved from
  13. Patterson, MD, C. R. (2017, August 14). Complications of Abdominal Hernia Mesh Repair. Retrieved from
  14. U.S. Food and Drug Administration. (2013, July 19). Class 2 Device Recall CQUR Edge Mesh. U.S. Department of Health & Human Services. Retrieved from
  15. U.S. Food and Drug Administration. (2013, July 19). Class 2 Device Recall CQUR VPatch Mesh. U.S. Department of Health & Human Services. Retrieved from
  16. U.S. Food and Drug Administration. (2013, July 19). Class 2 Device Recall CQUR TacShield Mesh. U.S. Department of Health & Human Services. Retrieved from
  17. Atrium. (2009, January 21). C-Qur Mesh. Retrieved from
  18. The JAMA Network. (2016, October 17). Study Finds Mixed Results for Use of Mesh for Hernia Repair. American Medical Association. Retrieved from
  19. U.S. Food and Drug Administration. (2018, January 22). 510(k) Premarket Notification. U.S. Department of Health & Human Services. Retrieved from
  20. News Medical Life Sciences. (2007, April 10). Atrium Medical receives FDA approval for Omega 3 surgical mesh product. Retrieved from
  21. Schreinemacher, M. H. F. et al. (2009, February 17). Degradation of mesh coating and intraperitoneal adhesion formation in an experimental model. BJS. Wiley Online Library. Retrieved from
  22. Atrium. (2011). Omega 2 Fatty Acid (O3FA) Bioabsorbable Coated Mesh. Retrieved from
  23. Atrium. (n.d.). C-Qur Mesh. Maquet Getinge Group. Retrieved from
  24. Maquet Getinge Group. (n.d.). C-QUR Mesh: O3FA coated polypropylene mesh. Retrieved from
  25. Atrium. (n.d.). C-QUR Mesh Instructions for Use. Retrieved from
  26. Zogbi, L. (2011). The Use of Biomaterials to Treat Abdominal Hernias. Retrieved from
  27. Kong, C.Y. et al. (2016). Inflammatory reaction to fish oil coated polypropylene mesh used for laparoscopic incisional hernia repair: a case report. Retrieved from
  28. McClain v. Atrium Medical Corporation et al. (2016, December 5). Complaint and Jury Demand. Case 1:16-cv-01095-SOH. Retrieved from
  29. Nguyen, M. T. et al. (2014, May). Comparison of outcomes of synthetic mesh vs suture repair of elective primary ventral herniorrhaphy. Retrieved from
  30. U.S. District Court, District of New Hampshire. (2018, May 29). In re: Atrium Medical Corp. C-QUR Mesh Products Liability Litigation; Case Management Order 3H. Retrieved from
  31. U.S. Judicial Panel on Multidistrict Litigation. (2019, July 16). MDL Statistics Report. Retrieved from
  32. Atrium. (2011). Omega 3 Fatty Acid (O3FA) Bioabsorbable Coated Mesh. Retrieved from
  33. U.S. Judicial Panel on Multidistrict Litigation. (2020, July 16). MDL Statistics Report - Distribution of Pending MDL Dockets by District. Retrieved from
  34. In Re: Atrium Medical Corp. C-Qur Mesh Products Liability Litigation. (2020, April 8). Defendants’ Motion To Extend Deadlines And Trial Date And For Expedited Consideration. Retrieved from
View All Sources
Who Am I Calling?

Calling this number connects you with a Drugwatch representative. We will direct you to one of our trusted legal partners for a free case review.

Drugwatch's trusted legal partners support the organization's mission to keep people safe from dangerous drugs and medical devices. For more information, visit our partners page.

(844) 807-8916